MDA-MB-231 D3H2LN-Luc TetOn-3G cell line

Human triple negative breast cancer MDA-MB-231 D3H2LN-Luc derivative cells stably expressing the Tet-On 3G (Tet3G) transactivator and luciferase, enabling the study of cell migration and the development of therapies that inhibit metastasis.

Contributors

Inventor Institute
Heather Mckinnon ; Justin Bower ; Daniel Croft Cancer Research UK, Glasgow: The Beatson Institute
SKU: 154147
Product description: This cell line stably expresses the Tet-On 3G (Tet3G) transactivator and luciferase and contains a tetracycline inducible promoter construct ready for cloning in a gene of interest. The cell line is a derivative of a human tiple negative breast cancer cell line shown to reliably metastasize to clinically relevant sites (the lungs and lymph nodes) when implanted orthotopically in mice (i.e. when implanted in the breast pad of mice). The cell line expresses luciferase enabling detection of the location of the cells using bioluminescent imaging. Unbekandt et al., 2014 introduced their genes of interest, the kinases MRCKβ, ROCK1 and ROCK2 under the tetracycline inducible promoter, to study the impact of their expression and inhibition on migration of the cells. Useful for the study of breast cancer cell cytoskeleton reorganisation, cell migration and the development of therapies that inhibit metastasis.
Conditional: Yes
Conditional description: When a gene of interest is introduced under the control of the tetracycline (Tet)-regulated transactivator Tet-On 3G expression can be induced by administration of doxycycline. Luciferase expression is non-conditional.
Production details: Generated an MDA-MB-231 D3H2LN-Luc cell line that expresses tetracycline (Tet)-regulated transactivator Tet-On 3G
Additional notes: Tet-On System owned by TET Systems GmbH & Co. KG.
Parental cell line: MDA-MB-231 D3H2LN-Luc
Disease: Cancer
Cat. #: 154147
Provenance and Ownership: The MDA-MB-231 D3H2LN-Luc TetOn-3G cell line is owned by Cancer Research UK. CancerTools supplies the MDA-MB-231 D3H2LN-Luc TetOn-3G cell line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing MDA-MB-231 D3H2LN-Luc TetOn-3G cell line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements.
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Breast cancer
Organism: Human
Tissue: Breast
Model: Reporter
Growth properties: Adherent cell line
Cancer Types In Detail: Triple negative breast (TNBC)
Format: Frozen
Storage conditions: Liquid Nitrogen
Shipping conditions: Dry ice
Growth medium: MEM/EBSS (Hyclone) supplemented with 10% Tet system approved fetal bovine serum (FBS) (Clonetech), 1 mM Sodium Pyruvate (Sigma), 2 mM L-glutamine (Gibco), 1× MEM non-essential amino acids (Gibco) plus penicillin-streptomycin (10 Units/ml and 10 μg/ml respectively).
Recommended controls: HeLa TetOn-3G
Mycoplasma free: Yes
Biosafety level: 1
References:

Unbekandt et al. 2014. Cell Commun Signal. 12:54. PMID: 25288205.

A novel small-molecule MRCK inhibitor blocks cancer cell invasion.

Related Tools for Cell lines

Cat. # Tool Name
151484 2fTGH Cell Line Key Info View Tool
151450 JIM3 Cell Line Key Info View Tool
151463 Omega-E Packaging Cell Line Key Info View Tool
151480 HEK293A EGFP-LC3 Cell Line Key Info View Tool
151630 PDVC57B Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.